PKC-9, PKC-zeta inhibitor

(RGNCY-0048)



Systematic Name:
4-(3-(4-(4-methylpiperazin-1-yl)-1H-benzo[d]imidazol-2-yl)-1H-indazol-6-yl)aniline

Molecular Weight: 423.52

Molecular Formula: $C_{25}H_{25}N_7$

SMILES:
NC1=CC=C(C2=CC(NN=C3C4=NC5=C(C=CC=C5N6CCN(C)CC6)N4)=C3C=C2)C=C1

Purity: 97.5%

Sulibility: DMSO, Hydrochloride

Pubmed Ref: 19097791

Description

PKC-9 is a 2-(6-phenyl-1H indazol-3-yl)-1H-benzo[d]imidazole derivative optimized to be a potent and selective inhibitor of protein kinase c-zeta (PKC-ζ; 5.18nM). The analog displays good selectivity over other PKC isoforms (α, βII, γ, δ, ε, μ, θ, η and ι/λ) and CDK-2, however it displays marginal selectivity against a panel of other kinases. The

inhibition of PKC-ζ is proposed to be a potential drug target for immune and inflammatory diseases.

References

Trujillo JI, Kiefer JR, Huang W et al. 2-(6-Phenyl-1H-indazol-3-yl)-1H-benzo[d]imidazoles: design and synthesis of a potent and isoform selective PKC-zeta inhibitor. Bioorg Med Chem Lett (2009); 19:908-11.

Rewards

Will you publish any experiments that use a Reagency product? Citing Reagency in your Materials and Methods can earn you discounts on your future purchases. It's easy! Simply list Reagency Pty Ltd as the source of the reagent in your paper, then email the reference to info@reagency.co.

Analytical Data

PO Box 9242, South Yarra, VIC, 3141, Australia +61(0)418570917 www.reagency.co

Compound ID: compound 9

EW4965-42-P1E3 MeOD Bruker_E_400MHz



Operator:

Date:

LCMS REPORT

```
Compound ID      : compound 9                                          ->
Sample ID        : EW4965-42-P1E2
Injection Date   : Tue, 28. Jun. 2016
Location         : P1-F-01
Inj. Vol.        : 1.0   uL
Acq   Method     : D:\METHODS\WUXIAB10.M
Data Filename    : D:\DATA\160628FG\EW4965-42-P1E2.D
Instrument       : LCMS-F
```



Report

Signal 1 : DAD1 E, Sig=220,8 Ref=off

#	Meas. Ret.	Height	Width	Area	Area %
1	1.655	1209.342	0.030	2269.391	100.000

Signal 2 : DAD1 D, Sig=254,8 Ref=off

#	Meas. Ret.	Height	Width	Area	Area %
1	1.654	1692.882	0.029	3133.165	100.000

Operator:_____

Date:_____



PO Box 9242, South Yarra, VIC, 3141, Australia +61(0)418570917 www.reagency.co

HPLC REPORT

Compound ID	: compound 9
Sample ID	: EW4965-42-P1E1
Vial#	: 66
Injection Volumn	: 1
Filename	: D:\data\2016\1606\160627\EW4965-42-P1E1.lcd
Method Name	: D:\Method\0-60AB_4min.lcm
Instrument &Column	: HPLC-D Kinetex EVO C18 4.6*50mm*5um
Run time	: 6/27/2016 5:34:31 PM



Integration result

PeakTable

PDA Ch1 220nm 4nm

Peak#	Ret. Time	USP Width	Resolution	Height	Area	Area %
1	0.974	0.136	0.000	2480	12920	2.458
2	1.581	0.040	6.893	346523	512682	97.542
Total				349003	525601	100.000

Operater : _____

Date : _____

PO Box 9242, South Yarra, VIC, 3141, Australia +61(0)418570917 www.reagency.co

HPLC REPORT

Compound ID : compound 9
Sample ID : EW4965-42-P1E1
Filename : D:\data\2016\1606\160627\EW4965-42-P1E1.lcd
Method Name : D:\Method\0-60AB_4min.lcm
Instrument &Column : HPLC-D Kinetex EVO C18 4.6*50mm*5um
Run time : 6/27/2016 5:34:31 PM



1 PDA Multi 2 / 254nm 4nm

Integration result

PeakTable

PDA Ch2 254nm 4nm

Peak#	Ret. Time	USP Width	Resolution	Height	Area	Area %
1	1.582	0.040	0.000	492430	720002	100.000
Total				492430	720002	100.000

Operater : _____

Date : _____

HPLC REPORT

Compound ID : compound 9
Sample ID : EW4965-42-P1E1
Filename : D:\data\2016\1606\160627\EW4965-42-P1E1.lcd
Method Name : D:\Method\0-60AB_4min.lcm
Instrument &Column : HPLC-D Kinetex EVO C18 4.6*50mm*5um
Run time : 6/27/2016 5:34:31 PM



1 PDA Multi 3 / 215nm 4nm

Integration result

PeakTable

PDA Ch3 215nm 4nm

Peak#	Ret. Time	USP Width	Resolution	Height	Area	Area %
1	0.973	0.339	0.000	5408	52639	7.930
2	1.581	0.040	3.213	413989	611149	92.070
Total				419396	663788	100.000

Operater : _____

Date : _____